News Releases

Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and research institutions across the Gulf Cooperation Council (GCC) region CENTOGENE to receive an

Results From Landmark Study Published in Brain Journal Collaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) Over seven years, a total of 45 affected individuals from 29 independent

Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that CENTOGENE CEO Kim Stratton will present in the virtual track at

Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance First half 2023 total revenues with double-digit growth of 15.1% at €24.6 million Both Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance

Results from pivotal study published in Diagnostics journal Confirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher disease Could predict clinical course of patients and improve personalized care CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept.

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received a written notification

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for August 2023.

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received notifications from the Nasdaq

Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options Inclusion of 602 patients from 47 countries represents the world’s largest and most heterogeneous Niemann-Pick type C1 disease (NPC1) cohort Study identified 287